The most‑cited independent voice on peptide therapy.
Science journalism, not medical advice — written for performance‑minded adults watching the peptide landscape ahead of FDA reclassification. We read the file. We date every claim. We sell nothing — yet.
A favourable vote is not a prescription you can fill in August.
PCAC — the Pharmacy Compounding Advisory Committee. Advisory, not binding; the rulemaking that follows is where access actually changes.
Editorial coverage
We read and date every file. Nothing is for sale.
PCAC review
FDA's advisory committee hears seven peptides at White Oak.
The vote
A non‑binding recommendation, taken peptide by peptide.
FDA rulemaking
The recommendation becomes a rule. Here is where access changes.
Legal access
Licensed pharmacies may dispense by prescription. We open.
Every peptide we track. One file each.
The peptides we cover — each with its evidence tag and where it sits in the FDA’s compounding review. We don’t promote a compound past its data, and we say so on every line.
What the literature actually says.
BPC-157's PCAC Recommendation Arrived Before Its Evidence Did
BPC-157 just got a federal advisory committee's recommendation, months after coming off a safety watchlist. Here's what actually happened in between, and what the recommendation does and doesn't mean for the vial in your fridge.
Thymosin Alpha-1 Corrects a Measurable Immune Deficit. Yours Might Not Have One Yet.
Semax: A Real Peptide With a Clinical Record the West Can't Audit
AOD-9604: The Growth Hormone Fragment That Failed Its Own Trial
Epithalon and the Telomere Question Nobody Has Answered
GHK-Cu Falls With Age. The One Human Skin Trial Found Nothing.
Science journalism. Not medical advice. We keep the difference visible.
How we rate the evidence.
Every claim carries one of three tags — human trials, animal data, or not yet known. If the literature is thin, the language is thin. We cite the trial phase, not a slogan.
What we don’t do.
No protocols. No dosing. No products, until the law changes. We don’t prescribe, and we don’t pretend a forum post is a study. We are not your doctor — we say so, repeatedly.
Who writes this.
Independent editors who read primary literature and FDA dockets directly. Every file is dated and re‑reviewed. When a file changes, the date changes with it.
Be on the list the day the window opens.
When reclassification lands, this becomes a physician‑supervised pharmacy. The waitlist goes first — and gets the briefing every week in the meantime. No spam. No products until it's legal. If we ever can't help you, we'll say so on screen.
You're on the list. Check your inbox for the first briefing.
We send the regulatory briefing weekly and tell you the day prescriptions become fillable in your state. Unsubscribe in one click.